secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001628280-24-036597
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q2 revenue jumps 186% to $73.8M; monetizes European royalties for $304.7M
--------------------------------------------------------------------------------

- Total revenue $73.8M (+186% YoY); U.S. product revenue $28.3M (+39% YoY).
- Monetized European royalties to OMERS for $304.7M; used proceeds to pay off Oberland facility and remove liens.
- Net loss $61.9M ($0.33 loss per share) vs $49.9M loss in Q2 2023; cash $189.3M.
- Retail prescription equivalents increased 11% in final four weeks of Q2; >21,000 prescribers.
- Reiterated FY2024 operating expense guidance $225M-$245M; patent extension for bempedoic acid to Dec 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024036597/0001628280-24-036597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024036597/espr-20240812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer